{"id":"c03a3cc43007","type":"article","url":"https://hartvaat.nl/2026/03/25/inspanningsecho-identificeert-hcm-patienten-die-baat-hebben-bij-mavacamten/","title":"Inspanningsecho identificeert HCM-patiënten die baat hebben bij mavacamten","title_en":"Role of Provocation and Exercise Imaging for the Identification of Candidates for Cardiac Myosin Inhibitors","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["aficamten","hypertrofische-cardiomyopathie"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag087","source_url":"https://doi.org/10.1093/eschf/xvag087","authors":["Jonas Erzeel","Sebastiaan Dhont","Marnicq van Es","Duhan Ulgar","Philippe Bertrand","Wilfried Mullens","Pieter Martens"],"significance":7,"published":"2026-03-25","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/","https://hartvaat.nl/kennis/diagnostiek/inspanningstest-loopband-fiets/"],"congress":"","summary_en":"Left ventricular outflow tract obstruction (LVOTO) drives symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Some patients show treatment-qualifying obstruction only during exercise echocardiography. In this single-centre retrospective cohort (56 symptomatic oHCM patients on mavacamten), 42.9% qualified exclusively during exercise echo. These patients did not have milder disease: functional limitation and exercise capacity were similar to those qualifying at rest or with Valsalva. By 24 weeks, both groups similarly achieved a non-obstructive gradient (<30 mmHg) and NYHA improvement. Exercise echocardiography thus identifies a substantial group of treatable oHCM patients missed by resting assessment.","created":"2026-07-03T10:32:18Z","updated":"2026-07-03T13:31:15Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Linkerventrikel-uitstroombaanobstructie (LVOTO) bepaalt de klachten bij obstructieve hypertrofische cardiomyopathie (oHCM). Sommige patiënten vertonen pas een behandel-kwalificerende obstructie tijdens inspanningsecho. In deze retrospectieve eencentrumstudie (56 symptomatische oHCM-patiënten op mavacamten) kwalificeerde 42,9% uitsluitend tijdens inspanningsecho. Deze patiënten hadden geen mildere ziekte: hun functionele beperking en inspanningscapaciteit waren vergelijkbaar met die van patiënten die al in rust of bij Valsalva kwalificeerden. Na 24 weken bereikten beide groepen even vaak een niet-obstructieve gradiënt (<30 mmHg) en NYHA-verbetering. Inspanningsecho spoort dus een aanzienlijke groep behandelbare oHCM-patiënten op die met een rustmeting wordt gemist.","abstract_original":"AIMS: Left ventricular outflow tract obstruction (LVOTO) drives symptoms and functional limitation in obstructive hypertrophic cardiomyopathy (oHCM). Some patients may only show treatment-qualifying obstruction during exercise echocardiography, yet their clinical profile and response to cardiac myosin inhibition are not well defined. This study compared the characteristics and therapeutic response of patients requiring exercise echocardiography to establish eligibility for mavacamten versus those meeting criteria at rest or during Valsalva. METHODS AND RESULTS: A single-center retrospective cohort of 56 symptomatic oHCM patients treated with mavacamten was evaluated. LVOTO was assessed at rest, with Valsalva, and during exercise; patients were classified as \"exercise\" or \"non-exercise\" LVOTO based on the provocation maneuver eliciting a qualifying gradient (≥50 mmHg). Hemodynamic (Valsalva LVOT gradient) and symptomatic (NYHA class) response were assessed at 12 and 24 weeks. A total of 42.9% qualified for mavacamten exclusively during exercise echocardiography. Although resting and Valsalva gradients were lower by definition, these patients showed similar baseline functional limitation and exercise capacity (pVO2; 17.9±7.4 vs. 16.8±5.5 mL/kg/min, p=0.550). By 24 weeks, most patients in both groups achieved non-obstructive gradients (<30 mmHg; 92.3% vs. 100.0%, p=0.371) and NYHA class improvement (77.3% vs. 92.3%, p=0.377), without significant between-group differences. CONCLUSION: Patients requiring exercise echocardiography to document qualifying LVOTO do not exhibit a milder disease phenotype and derive similar treatment benefits from mavacamten compared to those with resting or Valsalva-provoked obstruction. Exercise echocardiography identifies a substantial proportion of symptomatic HCM patients with significant LVOTO missed by resting assessment and is essential for guiding treatment eligibility."}